文献速递银屑病与炎症性皮肤病

司库奇尤单抗与依奇珠单抗在中重度斑块状银屑病中的药物留存率

Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.
PubMed 文献 · J Am Acad Dermatol · 2019-03-23

该丹麦全国队列研究基于DERMBIO登记数据,纳入接受司库奇尤单抗(368例)或依奇珠单抗(62例)标准剂量治疗的中重度斑块状银屑病患者,采用Kaplan-Meier法分析药物留存率。结果显示,依奇珠单抗的药物留存率高于司库奇尤单抗,尽管司库奇尤单抗组患者先前使用的生物制剂显著更少。

要点

  • 依奇珠单抗的药物留存率高于司库奇尤单抗。
  • 司库奇尤单抗组中生物制剂初治患者占40.7%,依奇珠单抗组占12.9%。
  • 司库奇尤单抗药物留存率在既往使用≥2种生物制剂的患者中最低。

核心结论

  • 依奇珠单抗的药物留存率高于司库奇尤单抗,尽管司库奇尤单抗组患者先前使用的生物制剂显著更少。

研究设计与样本

  • 基于丹麦DERMBIO登记数据的全国队列研究,纳入接受司库奇尤单抗(368例)或依奇珠单抗(62例)标准剂量治疗的中重度斑块状银屑病患者,采用Kaplan-Meier法分析药物留存率。

主要发现

  • 司库奇尤单抗组中生物制剂初治患者占40.7%,依奇珠单抗组占12.9%。
  • 依奇珠单抗组患者先前接受的治疗显著更多。
  • 12个月内,生物制剂初治的司库奇尤单抗和依奇珠单抗患者分别有23.5%和0.0%停止治疗。
  • 生物制剂初治和非初治患者的药物留存率,司库奇尤单抗均低于依奇珠单抗。
  • 在最长3年随访期间,司库奇尤单抗的药物留存率在既往使用≥2种生物制剂的患者中最低,其次是以司库奇尤单抗作为第二种生物制剂的患者。

局限性

  • 患者总数和随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biologics targeting interleukin 17 are increasingly being used for treatment of moderate-to-severe psoriasis, but data on drug survival for these therapies remain scarce. OBJECTIVES: To investigate the drug survival of secukinumab and ixekizumab in a nationwide cohort of patients with psoriasis in Denmark. METHODS: Using DERMBIO, we examined Danish patients receiving treatment with secukinumab or ixekizumab according to the standard in-label dosing. Kaplan-Meier plots were used to present survival curves. RESULTS: In all, 368 and 62 patients received treatment with secukinumab and ixekizumab, respectively. In total, 40.7% and 12.9% of secukinumab- and ixekizumab-treated patients were bionaive. Ixekizumab-treated patients had received significantly more previous treatments. Over 12 months, 23.5% and 0.0% of bionaive secukinumab- and ixekizumab-treated patients discontinued therapy, respectively. Drug survival for bionaive and non-naive patients was lower for secukinumab than for ixekizumab. During the maximum 3 years of follow-up, secukinumab drug survival was lowest for patients who had previously been treated with 2 or more biologics, followed by patients treated with secukinumab as their second-ever biologic. LIMITATIONS: The total number of patients and follow-up time were modest. CONCLUSIONS: Drug survival was higher for ixekizumab even though secukinumab-treated patients had been treated with significantly fewer biologics before starting this drug.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Egeberg A, Bryld LE, Skov L, et al. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019. PMID: 30914343. doi:10.1016/j.jaad.2019.03.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。